title: Therapeutic use of muscarinic acetylcholine receptor peptide to prevent mice chagasic cardiac dysfunction.
abstract: Therapeutic use of a peptide corresponding to the aminoacid sequence of the second extracellular loop of human M2 muscarinic acetylcholine receptor (M2 mAChR peptide) was studied. Expression and biological activity of M2 mAChR in association with circulating M2 mAChR-related antibodies in cardiac tissue from chagasic mice were evaluated. Mice infected or not with trypomastigotes Tulahuen strain either treated or not treated with M2 mAChR peptide were sacrificed at 8-9 weeks post-infection. Morphological, binding and contractility studies were performed on all animal groups. Hearts from infected mice showed a mAChR-related dysfunction, with a decrease in heart contractility, impaired response to exogenous mAChR agonist (carbachol) and a significant reduction of mAChR binding sites. Treating infected mice with M2 mAChR peptide reversed those effects. Moreover, autoantibodies from infected mice recognized the M2 mAChR peptide. In addition, serum from infected mice and the corresponding affinity purified IgG was capable of interacting with cardiac mAChR, reducing the number of binding sites and inhibiting the contractile response to exogenous agonist. In conclusion, (1) the development of alterations in mAChR related to cardiac dysfunction, may be associated with the presence of circulating antibodies against these receptors and (2) the chronic treatment with M2 mAChR peptide prevented infected mice heart dysfunction. The mechanism could be explained by the ability of the M2 mAChR peptide to inhibit the chronic interaction of autoantibodies specific to mAChR. The implication of M2 mAChR peptide treatment in the host's immune response is discussed.
authors.affiliation: Pharmacology Department of School of Medicine, Pharmacology Unit of School of Dentistry, University of Buenos Aires, Argentine National Research Council, Argentina. leo@farmaco.odon.uba.ar
authors.forename: Leonor
authors.initials: L
authors.lastname: Sterin-Borda
authors.forename: Lilian
authors.initials: L
authors.lastname: Joensen
authors.forename: Carolina
authors.initials: C
authors.lastname: Bayo-Hanza
authors.forename: Mónica
authors.initials: M
authors.lastname: Esteva
authors.forename: Enri
authors.initials: E
authors.lastname: Borda
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D016275:Atrial Function / Q000187:drug effects; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects; D002217:Carbachol / Q000494:pharmacology; D002598:Chagas Cardiomyopathy / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control*; D006321:Heart / Q000503:physiopathology; D007074:Immunoglobulin G / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000737:chemistry / Q000627:therapeutic use*; D011813:Quinuclidinyl Benzilate / Q000378:metabolism / Q000494:pharmacology; D043585:Receptor, Muscarinic M2; D011976:Receptors, Muscarinic / Q000737:chemistry*; D014349:Trypanosoma cruzi / Q000302:isolation & purification
chemical_list: D007074:Immunoglobulin G; D010446:Peptide Fragments; D043585:Receptor, Muscarinic M2; D011976:Receptors, Muscarinic; D011813:Quinuclidinyl Benzilate; D002217:Carbachol